Dr. Stefan Walzer
Dr. Stefan Walzer has more than 15 years experience in payer strategy, pricing, health economics and reimbursement submissions and is the founder and general manager of MArS Market Access & Pricing Strategy GmbH based in Germany. He previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. Dr. Walzer was also the Global Payer Strategy Leader for various products and compounds of F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Dr. Walzer is experienced in the development of early payer strategies and the related evidence generation. Furthermore he is also capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he also teaches at the Master course of Consumer Health Care at the Charité in Berlin (Germany) and is a tutor in market access and health technology assessment at the State University of Baden-Wuerttemberg (Germany).
From 2018-2019 Dr. Walzer was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is a leading member of the Special Interest group for Medicial Nutritions at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Dr. Walzer is also a member of the Austrian Health Economic Association (ATHEA) and the newly founded Swiss Health Economic Association. Additionally, he is also a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition.
Dr. Walzer received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a Diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 100 scientific abstracts. Furthermore Dr. Walzer is the Editor in Chief of the German Journal of ClinicoEconomics (www.germanjournal-clinicoeconomics.de) and the lead author of the book chapter “Vergütungshöhe und Preissetzung” [Reimbursement value and pricing] in Business Planning in Health Care (http://www.springer.com/de/book/9783658081850).
Mr. Lutz Vollmer is a health economic expert with a special focus on health geography and the German market access system. He was working in Research and Administration at the Universities of Tuebingen and Kiel (Germany) for over 12 years while he was also executing primary market research projects as a free lancer. Since 2014 he supports the MArS Team as a Health Economist with a focus on payer research, health geographic solutions and the analysis of German market access decisions. In the last years he was running various interview projects in the AMNOG environment, developed successful reimbursement pathways and executed systematic literature reviews in the field of pharmaceuticals for AMNOG submissions. Furthermore he has experience in the development of reimbursement submissions for medical devices and drugs.
Mr. Vollmer is a member of the working group for “E-Health” and “Innovation in hospitals” at the German Health Economic Association (DGGÖ).
Lutz Vollmer studied geography at the Universities of Tuebingen and Stuttgart (Germany) and at the Portland State University (Oregon, USA). He holds a Master of Science in Geography and an HTA-certificate from the Free University of Berlin (Germany). Mr. Vollmer is author of several articles including research presentations and papers in geography and health economics. Also at the University of Applied Sciences of Rottenburg / Neckar (Germany), Mr. Vollmer teaches fundamentals and deeper aspects of human geography in study programs of regional management.
Wolfgang Schleich is a health economist by education and graduated from the University of Bayreuth (Germany) and Trondheim Business School (Norway).
Mr. Schleich brings prior experience through a number of assignments including the Global HTA & Payment Policy department at F. Hoffmann-La Roche, the German affiliate at Novartis, with the health consultancy Oberender & Partner, and the Institute for Health Economics & Clinical Epidemiology, a research institute affiliated with the University of Cologne. Additionally, he gained experience at MArS with respect to strategic pricing as well as the development of reimbursement submissions (e.g. AMNOG). Furthermore he planned and executed various payer researches and advisory boards.
Mr. Schleich wrote his master’s thesis in the topic of “Value of the HTA Core Model as Strategic Planning Framework for Product-Specific Evidence” at Roche Pharma and worked following his graduation as Associate Health Economist in its Global Health Economics department. In this position he supported affiliates in their reimbursement application process. In parallel to this work, he has contributed to a political think tank (Young Lions Health Parliament) relating to the future of the German health care system.
Dunia Krueger is a physiotherapist by training and has over 25 years work experience especially in the areas of orthopedics, surgery and oncology. She is experienced in medical accounting and coding as well as in direct discussions and negotiations with health insurances. Dunia Krueger is also knowledgable in cost and medical data searching and its interpretation.
Sebastian Krenberger is a health economist and holds a Master in Public Health from the University of Applied Sciences Fulda (Germany). Additionally, Sebastian is a (intensive care) nurse with more than 7 years of experience in various departments and responsibilities at the clinic Fulda and the university hospital of Kiel.
Sebastian has a broad medical understanding in various disease areas and the process within hospitals. Furthermore he is a public health and market process expert for Germany.
Mr. Roman Spelsberg is a health economist with a focus on sustainable Market Access for innovations in the German healthcare system.
Mr. Spelsberg worked in several roles in the pharmaceutical industry and at a German statutory health insurance since 2015. During his dual study program in cooperation with the Roche Pharma AG, he was operating in Market Analytics, Marketing and Market Access. While working as Market Access Manager for ALK-Abelló Arzneimittel GmbH, he successfully developed Market Access strategies, payer communications and pricing models.
The primary research focus of Mr. Spelsberg are innovative pricing models. In his master thesis, which he developed in cooperation with the DAK-Gesundheit, he analysed whether outcomes-based risk-share agreements can address the (pricing and evidence) challenges of Advanced Therapy Medicinal Products (ATMPs).
Mr. Spelsberg discusses current challenges for the German health care system as member of the German Health Economic Association (DGGÖ) and the German Society for Market Access (DFGMA).
Mr. Spelsberg studied Healthcare Management at the Cooperative State University Baden-Wuerttemberg (Germany) with a semester at the University of California in Santa Barbara (USA). He obtained a Master of Science in Healthcare Policy, Innovation and Management from Maastricht University (Netherlands) and a certificate in Negotiations from the Harvard Business School (USA).
Dr. Andreas Voss
Dr. Voss is an internist with a focus on oncology. After 10 years of clinical practice at the University Hospital in Hamburg Eppendorf, he started his career in the pharmaceutical industry, where he was responsible for global clinical development, regulatory affairs and marketing of numerous drugs. He has worked in large companies (AstraZeneca, Roche) as well as in small and medium sized companies and gained broad experience in various roles. Dr. Voss has led several clinical development programs and has been responsible for over 150 regulatory processes, including ‘orphan drugs’ and pediatric indications. Prior to becoming an independent consultant, Dr. Voss served as Managing Director at Caris Life Sciences International, where he was responsible for the development and sales of assays for personalized medicine.
Andreas Voss is the Clinical Science Advisor at MArS.
Mr. Feuerstein is a Health Economic Writer at MArS. Before joining MArS he gained much experience in a variety of industries including pharmaceuticals and the Fulda Health Authority. Here he was responsible for summarising complex data and to prepare it for decision-making.
Furthermore, Mr. Feuerstein wrote various scientific papers on relevant topics. He completed his Master’s degree in Public Health at the University of Applied Sciences Fulda. The focus of his studies was on occupational health management and environment, and health.
Previously, Mr. Feuerstein completed an apprenticeship as a media designer and worked independently in communications for 15 years. His strength lies in coordinating complex, interrelated processes and connecting theory and practice.
Ms. Walzer has more than 11 years of experience in practice management of outpatient medical practices and affiliated doctors in Germany in the field of dermatology, onco-dermatology, surgery and orthopedics.
Ilse-Barbara Oelze is a Market Access Manager at MArS. Previously she worked at Certara Evidence & Access in Germany where she gained substantial experience in pricing and market access consulting projects. She is also a specialist for pricing and cost evaluations for the German market.
Ilse-Barbara holds a Master in Health Economics and Pharmacoeconomics (MPHE) from Pompeu Fabra University, School of Management in Barcelona. She also holds a degree in business administration (equivalent to a MS in business administration) from the University of Applied Sciences, Neu-Ulm, with a focus in Hospital Management. Additionally, she has studied law at the University in Freiburg.
Prior Ilse- Barbara gained experience in health care politics and health care management as well as in developing DRGs and costing of ambulant treatments. She has held several positions within hospitals and SHIs (statutory health insurances) in Germany. Through her professional experiences and graduate education, she has gained strong analytical skills and a global strategic vision.